NCT05357989Phase 3Completed

A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2023-12-04Actual

Enrollment · participants523Actual

Source updated2025-03-03Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Parkinson's Disease, Idiopathic

Treatments or interventions studied

buntanetap/posiphenDrugAlso known as Posiphen Tartrate, ANVS401
PlaceboDrug

Primary outcomes · main study measures

Read the study measures

measure: Change From Baseline to Month 6 in MDS-UPDRS Part II (OFF-state); description: Change in the Score from the MDS- Unified Parkinson's Disease Rating Scale (UPDRS) Parts II from Baseline to the End of Trial. MDS-UPDRS Part II (Motor experiences of daily living) has 13 items and the score ranges from 0-52, with higher scores reflecting greater severity.; timeFrame: Baseline and 6 months visits

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history